method for determining the sensitivity of cancer cells in cervical cancer to radiation therapy

The research endeavor meticulously analyzed genetic profiles from 100 cervical cancer patients, categorizing them into distinct groups based on their radiosensitivity. group 1, comprising 57 patients, exhibited sensitivity to radiation therapy, while the remaining 43 patients formed group 2, demonstrating resistance. intriguingly, the study uncovered stark contrasts in gene copy number variations (cnvs) between the two groups. in radiation- sensitive patients, a notable downregulation was observed in genes such as h2afx, atm, chek1, and linc00400, with reductions ranging from 1.7 to 4.5 times compared to normal cells. conversely, genes like casp-1, -4, -5, cyp1-a1, -a2, and gpx4 displayed significant upregulation, increasing by factors of 1.8 to 2.7 times. the resistant group presented an opposing pattern, with a pronounced decrease in casp4, casp5, cyp1a1, and yap1 expression, dropping by 1.4 to 3.3 times. meanwhile, genes including h2afx, chek1, erbb2, and birc2 showed elevated copy numbers, surging by 2.8 to 3.5 times relative to normal cervical cells. using integrated molecular and computational approaches, we identified a panel of key replication markers—h2afx, chek1, erbb2, birc2, linc00400, casp4, casp5, and cyp1a1—that play crucial roles in dna damage response, apoptosis, and cell cycle regulation, directly influencing radiation sensitivity. chek1, erbb2, birc2, linc00400, casp4, casp5, and cyp1a1—detectable in both tissue samples and extracellular dna. these findings pave the way for precision diagnostic tools to predict cervical cancer responsiveness to radiation therapy, facilitating personalized treatment strategies and improving clinical outcomes.